
Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SYNGENE | BSE
3.10
0.41%
Healthcare
Biotechnology
30/09/2023
30/11/2023
752.05
750.00
758.05
741.70
Syngene International Limited a contract research and manufacturing company provides drug discovery and development services in India the United States and internationally. The company provides discovery chemistry services such as medicinal and synthetic chemistry library and peptide synthesis biomolecules organic electronic materials and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering cell line development hybridoma technology sequencing protein sciences screening and assay biology DMPK in vivo pharmacology toxicology and biologicals. It also offers exploratory/discovery in vitro and genetic and developmental and reproductive toxicology services as well as acute sub-chronic and chronic toxicity studies; and chemical formulation analytical and clinical development services as well as commercial manufacturing services. In addition the company provides lead generation preclinical development API and drug product development services; and clinical trial management pharmacokinetic analysis/bioanalytical central lab biometrics and clinical data management regulatory medical monitoring pharmacovigilance and medical writing services. Further it offers other drug modalities which include peptides oligonucleotide synthesis antibody drug conjugate PROTACs and CAR T-cell therapy services. The company serves pharmaceutical biotechnology nutrition animal health consumer goods specialty chemical and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru India. Syngene International Limited is a subsidiary of Biocon Limited.
View LessPositive Momentum
Strength based on increasing price with high volume
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
Weak P/E, and PEG ratio indicator
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
15.2%1 month
18.2%3 months
26.0%6 months
27.0%60.22
0
7.18
0.21
0.14
25.90
8.60
0
10.47B
302.34B
3.63B
0.07
18.39
14.60
18.50
13.91
0
0
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
44.00
Range1M
84.60
Range3M
188.60
Rel. volume
1.53
Price X volume
14.51M